---
title: "Bide Pharmaceuticals establishes a biotechnology subsidiary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240744094.md"
description: "According to the Qichacha APP, recently, Shanghai Anbida Biotechnology Co., Ltd. was established, with Wan Jiangbo as the legal representative. The business scope includes: research and development of biochemical products technology; sales of new catalytic materials and additives, etc. Qichacha's equity penetration shows that the company is wholly owned by Bide"
datetime: "2025-05-19T02:20:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240744094.md)
  - [en](https://longbridge.com/en/news/240744094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240744094.md)
generator: "portal-rs"
---

# Bide Pharmaceuticals establishes a biotechnology subsidiary

According to the Qichacha APP, Shanghai Anbida Biotechnology Co., Ltd. was recently established, with Wan Jiangbo as the legal representative. The business scope includes: research and development of biochemical products technology; sales of new catalytic materials and additives, etc. Qichacha's equity penetration shows that the company is wholly owned by Bide

### Related Stocks

- [688073.CN](https://longbridge.com/en/quote/688073.CN.md)

## Related News & Research

- [If You Invested $1,000 in Pepe Coin When Elon Musk Shared a Pepe Meme, Here’s How Much You’d Have Today](https://longbridge.com/en/news/296651068.md)
- [The Sandbox SAND Exploit: $49B in New Tokens Flood Base](https://longbridge.com/en/news/296678246.md)
- [Oura exploring how its ring could detect brain hemorrhages after Bill Ackman suggests it could have helped his daughter](https://longbridge.com/en/news/296658401.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/296498950.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**